Folitixorin - ADVENTRX

Drug Profile

Folitixorin - ADVENTRX

Alternative Names: 5-10 Methylenetetrahydrofolate; 5-FU biomodulator - ADVENTRX; ANX-510; CoFactor; Methylenetetrahydrofolic acid

Latest Information Update: 30 Oct 2008

Price : $50

At a glance

  • Originator Sahlgrenska University Hospital; University of Southern California
  • Developer ADVENTRX Pharmaceuticals
  • Class 3-ring heterocyclic compounds; Antineoplastics; Chemoprotectants; Chemosensitisers; Folic-acids; Imidazolidines; Pyrimidinones; Small molecules; Tetrahydrofolates
  • Mechanism of Action Antimetabolites; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 23 Oct 2008 Discontinued - Phase-II for Breast cancer in Argentina (IV)
  • 23 Oct 2008 Discontinued - Phase-II for Breast cancer in Mexico (IV)
  • 23 Oct 2008 Discontinued - Phase-II for Breast cancer in Peru (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top